CN102070531A - Microwave radiation injury protection medicines - Google Patents
Microwave radiation injury protection medicines Download PDFInfo
- Publication number
- CN102070531A CN102070531A CN 201110000077 CN201110000077A CN102070531A CN 102070531 A CN102070531 A CN 102070531A CN 201110000077 CN201110000077 CN 201110000077 CN 201110000077 A CN201110000077 A CN 201110000077A CN 102070531 A CN102070531 A CN 102070531A
- Authority
- CN
- China
- Prior art keywords
- microwave radiation
- medicines
- radiation injury
- medicine
- medicines structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LQUFHIPRZXGNBM-UHFFFAOYSA-N CC1(C)NC(C)(C)C1 Chemical compound CC1(C)NC(C)(C)C1 LQUFHIPRZXGNBM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses microwave radiation injury protection medicines shown in a structural general formula (I). Molecules of the medicines contain nitronyl nitroxide radical structural units, the medicines have the characteristic of removing harmful free radicals in an organism subjected to microwave radiation injury, and have obvious effect of preventing and treating the microwave radiation injury.
Description
Technical field
The invention provides the medicines structure that a class can effectively alleviate the microwave radiation damage, belong to medical technical field.
Background technology
Microwave is meant the radiowave that wavelength is very short, frequency is very high, is the part of frequency electromagnetic waves, and frequency is at 300MHz ~ 300GHz, and wavelength is 1m ~ 1mm.Along with science and technology development, microwave technology has been widely used in radar, microwave communication, television transmission and microwave heating equipment, relate to being extensive use of of every field, especially modern communication instruments such as military affairs, communication, industry, medical treatment, the personnel of contact microwave radiation are more and more.
Research work since the relevant microwave irradiation effect of people's thirties in last century.Studies show that: slight microwave radiation of short period of time can make skin produce burning sensation, can damage organs such as retina, eyes, sexual organ, microwave radiation (as radar Operation and maintenance personnel) damage for a long time, show as unify endocrine system disorder and involve cardiovascular systems, immunity and metabolic function of central nervous system, cause multiple organ injury, produce symptoms such as neurasthenia syndrome, white corpuscle, platelet count minimizing, thereby human body is produced a series of harmful effects.
Microwave radiation becomes three big physical property public hazards side by side with noise and radio isotope.At present, the research of microwave radiation protection medicine is reported seldom.The chemicals amifostine (WR2721) and the hormone medicine E838 of listing only have protection effect to ionizing rays.Bibliographical information herbal mixture weidakang has certain microwave radiation protective effect.Currently still lack very much microwave radiation protection medicine efficient, low toxicity.
The invention provides a class novel microwave radioprotector structure, have important practical value.
Summary of the invention
The medicine that the purpose of this invention is to provide one class preventing and control or the protection of treatment microwave damage.
The medicines structure of general formula (I) expression,
R1 to R5 independently is selected from H, NO
2, OH, OCH
3, halogen; A kind of preferred scheme is: four substituting groups are hydrogen among the R1 to R5, and for example R2 is OH, and R1, R3, R4, R5 are H.Another kind of preferred scheme is: three substituting groups are hydrogen among the R1 to R5, and for example R1 is OH, and R2 is NO
2, R3, R4, R5 are H.Described halogen is F, Cl or Br.
The application of said medicine structure in preparation control and treatment microwave radiation damage medicine.
A kind of pharmaceutical composition, it contains the medicines structure of general formula (I) expression, and one or more pharmaceutical carriers or vehicle, and this medicine can be made tablet, capsule, powder, pill, granule or emulsion.
Synthesizing of above-claimed cpd with R
1~ R
5The phenyl aldehyde that replaces is a raw material, with 2, and 3-dimethyl-2,3-dihydroxy amido butane carries out condensation and forms, for example:
Foundation is route of synthesis similarly, can synthesize to obtain following structure medicament:
Preliminary pharmacodynamics test proves that damage has provide protection to such medicine to microwave radiation, can significantly improve the resistance of oxidation of body, reduces the content of rat blood serum alanine aminotransferase activity, aspartic transaminase activity and blood urea nitrogen.
Embodiment
Embodiment 1: compound 1 synthetic
With 1.22 g(10.0 mmol) p-Hydroxybenzaldehyde and 1.48 g(10.0 mmol) dihydroxylamine is dissolved in the 50 mL methyl alcohol back flow reaction 24 h.Have a large amount of white insolubless to generate, filter, filter cake washs with small amount of methanol.Filter cake is suspended in 50.0 mL CH
2Cl
2In, the ice-water bath cooling adds 30.0 mL NaIO
4(1.7 g) aqueous solution stirs stopped reaction behind 15 min.Behind the standing demix, water CH
2Cl
2Extracting twice merges organic phase, and dried overnight is filtered, removal of solvent under reduced pressure, and column chromatography purification gets product 1.12 g, productive rate 45%.Mp:?137-139℃.?R
f=0.33?(CHCl
3/CH
3OH,?20:1).?EI-MS(m/z)?250.1[M]
+.?IR(KBr)?3340?(OH);?1590,?1450,?1380,?880,?800,?690?cm
-1.?Anal.?Calcd?forC
13H
17N2O
3:?C,?62.64;?H,?6.87;?N,?11.24.?Found:?C,?62.71;?H,?6.94;?N,?11.18.?ESR:?aN?=?8.18?G,?g?=?2.00994.
Embodiment 2: compound 2 synthetic
With 1.88 g(10.0 mmol) to 2,4 dichloro benzene formaldehyde and 1.48 g(10.0 mmol) dihydroxylamine is dissolved in the 50 mL methyl alcohol back flow reaction 24 h.Have a large amount of white insolubless to generate, filter, filter cake washs with small amount of methanol.Filter cake is suspended in 50.0 mL CH
2Cl
2In, the ice-water bath cooling adds 30.0 mL NaIO
4(1.7 g) aqueous solution stirs stopped reaction behind 15 min.Behind the standing demix, water CH
2Cl
2Extracting twice merges organic phase, and dried overnight is filtered, removal of solvent under reduced pressure, and column chromatography purification gets product 1.55 g, productive rate 51%.Mp:?123-125℃.?R
f?=?0.54(CHCl
3/CH
3OH,?20:1).?EI-MS?(m/z)?302?[M]
+.?IR?(KBr)?1590,?1450,?1365,?1000,?825,?870?cm_1.?Anal.?Calcd?for?C
13H
15N
2O
2Cl
2:?C,?51.67;?H,?5.00;?N,?9.27.?Found:?C,?51.73;?H,?5.08,?N?9.35.?ESR:?a
N?=?8.15?G,?g?=?2.00997.
Embodiment 3: compound 6 synthetic
With 1.53 g(10.0 mmol) 2-fluorine formaldehyde and 1.48 g(10.0 mmol) dihydroxylamine is dissolved in the 50 mL methyl alcohol back flow reaction 24 h.Have a large amount of white insolubless to generate, filter, filter cake washs with small amount of methanol.Filter cake is suspended in 50.0 mL CH
2Cl
2In, the ice-water bath cooling adds 30.0 mL NaIO
4(1.7 g) aqueous solution stirs stopped reaction behind 15 min.Behind the standing demix, water CH
2Cl
2Extracting twice merges organic phase, and dried overnight is filtered, removal of solvent under reduced pressure, and column chromatography purification gets product 1.40 g, productive rate 56%.Mp:?112-114℃.?R
f=0.52?(CHCl
3/CH
3OH,?20:1).?EI-MS?(m/z)?251?[M]
+.?IR?(KBr)?1610,?1450,?1370,?1135,?770?cm
-1.?Anal.?Calcd?for?C
13H
16N
2O
4:?C,?62.14;?H,?6.42;?N,?11.15.?Found:?C,?62.23;?H,?6.58;?N,?11.09.?ESR:?a
N=8.15G,?g?=?2.00996.
Embodiment 4: the microwave radiation protection pharmacodynamic experiment of nitroxyl free radical (structural formula 1)
(1) testing program
Experimental subjects: the Wistar rat, male and female half and half are provided by The Fourth Military Medical University's Experimental Animal Center.
Experimental technique: rat is divided into 4 groups by the table of random number method, normal control group, microwave radiation group, medicine control group, microwave radiation+medication therapy groups, 12 every group.Except that the normal control group, each organizes rat all through microwave irradiation 1 time, times 5 min.Microwave radiation+medication therapy groups rat begins gastric infusion in irradiation back 8 h, and 1 time/d, be divided into high 0.5mM/kg, middle 0.25mM/kg, low three dosage groups of 0.1mM/kg (every rat gives 0.5mL), put to death behind continuous use 4 d.The administration in a manner described of medicine control group, but irradiating microwaves not.Each is organized rat and all puts to death at 4d, adopts the anesthesia of 200 g/L urethanes, abdominal aortic blood, and separation of serum is surveyed and is respectively organized indexs such as rat alanine aminotransferase, aspartic transaminase, blood urea nitrogen.
(2) experimental result
As shown in table 1, behind the microwave irradiation, compare 4 d group rat blood serum alanine aminotransferase, aspartic transaminase activity and all significantly risings (P＜0.05) of urea nitrogen content after the radiation with the normal control group.The medicine control group is compared every test index no significant difference with the normal control group.4 d organized (P＜0.05) after microwave radiation+pharmacological agent 4 d group rat blood serum alanine aminotransferase activity, aspartic transaminase and urea nitrogen content significantly were lower than radiation.
Embodiment 5: the microwave radiation protection pharmacodynamic experiment of nitroxyl free radical (structure 2 ~ 5)
(1) testing program is with embodiment 1.
(2) experimental result sees Table 2.
Claims (8)
1. the medicines structure of general formula (I) expression,
R1 to R5 independently is selected from H, NO
2, OH, OCH
3, halogen.
2. medicines structure according to claim 1 is characterized in that: any four substituting groups are hydrogen among the R1 to R5.
3. medicines structure according to claim 1 is characterized in that: any three substituting groups are hydrogen among the R1 to R5.
4. according to one of any described medicines structure of claim 1 to 3, it is characterized in that: halogen is F, Cl or Br.
5. according to one of any described medicines structure of claim 1 to 3, it is characterized in that: R1 to R5 independently is selected from H, NO
2, OH, OCH
3
6. the application of the described medicines structure of claim 1 in preparation control and treatment microwave radiation damage medicine.
7. pharmaceutical composition, it contains one of any described medicines structure of claim 1 to 3, and one or more pharmaceutical carriers or vehicle.
8. according to the described pharmaceutical composition of claim 7, it is characterized in that: this medicine is tablet, capsule, powder, pill, granule or emulsion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110000077 CN102070531A (en) | 2011-01-04 | 2011-01-04 | Microwave radiation injury protection medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110000077 CN102070531A (en) | 2011-01-04 | 2011-01-04 | Microwave radiation injury protection medicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102070531A true CN102070531A (en) | 2011-05-25 |
Family
ID=44029312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110000077 Pending CN102070531A (en) | 2011-01-04 | 2011-01-04 | Microwave radiation injury protection medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102070531A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102070532A (en) * | 2011-01-25 | 2011-05-25 | 中国人民解放军第四军医大学 | Anti-tumor medicament structure |
| CN102229566A (en) * | 2011-05-16 | 2011-11-02 | 中国人民解放军第四军医大学 | Structure of drug for treating neurodegenerative disease |
| CN104844516A (en) * | 2015-03-31 | 2015-08-19 | 西安工业大学 | Dual-functional radiation damage protection drug containing phenols and synthesis and application thereof |
| CN108997422A (en) * | 2018-06-22 | 2018-12-14 | 中国人民解放军第四军医大学 | The preparation of Mitochondrially targeted radioprotectant and its application in radiation injury protection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1743314A (en) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 2-substituted-4,4,5,5-tetramethyl-1-oxyimidazoline, and its synthesis and use |
| CN1743315A (en) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 2-substituted-4,4,5,5-tetramethyl-1-hydroxyimidazoline, and its synthesis and use |
| CN1743316A (en) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 2-substituted phenyl-4,4,5,5-tetramethyl-1,3,-dioxy imidazolines, their preparation and pharmaceutical use |
-
2011
- 2011-01-04 CN CN 201110000077 patent/CN102070531A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1743314A (en) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 2-substituted-4,4,5,5-tetramethyl-1-oxyimidazoline, and its synthesis and use |
| CN1743315A (en) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 2-substituted-4,4,5,5-tetramethyl-1-hydroxyimidazoline, and its synthesis and use |
| CN1743316A (en) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 2-substituted phenyl-4,4,5,5-tetramethyl-1,3,-dioxy imidazolines, their preparation and pharmaceutical use |
Non-Patent Citations (2)
| Title |
|---|
| 《European Journal of Medicinal Chemistry》 20070113 Ming Zhao et al. Studies on log P, retention time and QSAR of 2-substituted phenylnitronyl nitroxides as free radical scavengers 第955－965 1－5 第42卷, * |
| 《军事医学科学院院刊》 20090831 文静等 微波辐射损伤及防护研究进展 第385－387 1－8 第33卷, 第4期 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102070532A (en) * | 2011-01-25 | 2011-05-25 | 中国人民解放军第四军医大学 | Anti-tumor medicament structure |
| CN102070532B (en) * | 2011-01-25 | 2012-12-05 | 中国人民解放军第四军医大学 | Anti-tumor medicament structure |
| CN102229566A (en) * | 2011-05-16 | 2011-11-02 | 中国人民解放军第四军医大学 | Structure of drug for treating neurodegenerative disease |
| CN104844516A (en) * | 2015-03-31 | 2015-08-19 | 西安工业大学 | Dual-functional radiation damage protection drug containing phenols and synthesis and application thereof |
| CN104844516B (en) * | 2015-03-31 | 2017-12-19 | 西安工业大学 | Containing the difunctional radiation injury protection medicine of phenols and its synthesis and application |
| CN108997422A (en) * | 2018-06-22 | 2018-12-14 | 中国人民解放军第四军医大学 | The preparation of Mitochondrially targeted radioprotectant and its application in radiation injury protection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109575024B (en) | Matrine phenolate and preparation method and application thereof | |
| CN102070531A (en) | Microwave radiation injury protection medicines | |
| CN102432601A (en) | Mangiferin pentaethylated derivative | |
| CN106188209B (en) | A kind of melbine conjugate for having antitumor and activity of resisting tumor metastasis concurrently and its application | |
| CN104844516B (en) | Containing the difunctional radiation injury protection medicine of phenols and its synthesis and application | |
| CN102060849B (en) | Dual functional radiation damage preventing and treating medicaments | |
| CN103417563A (en) | Application of aurantiamarin to preparation of medicine for treating acute and chronic bronchitis | |
| CN107540569B (en) | Laminarinic ester group bromo-oxamide derivative with anticancer activity and composition thereof | |
| CN101152251A (en) | Application of magnolia bark and its active ingredient in preparing medicament for treating tumour stem cell | |
| JPWO2007105353A1 (en) | Plant-derived malignant tumor therapeutic agent | |
| CN114957355B (en) | Preparation method of natural capsaicin glycoside | |
| CN102432603A (en) | Preparation method and pharmacological action of mangiferin hexa-butylated derivative | |
| CN103585211A (en) | Application of Dorema ammoniacum resin extract in preparation of drugs treating leukemia | |
| CN103641688B (en) | Mailuoning dihydroanthracene and preparation method and application thereof | |
| CN111808052B (en) | Furan sulfonic acid compound and preparation method and application thereof | |
| CN107098907A (en) | A kind of bicyclic alcohols folate conjugate and its production and use | |
| CN105418597A (en) | Novel 1,3-dyhydroxylxanthone derivative and application thereof in medicines | |
| CN107007600B (en) | Antitumor pharmaceutical composition with lipoyunaconitine as active ingredient and application thereof | |
| CN105820045A (en) | Medicinal composition of cefadroxil and medicinal application of medicinal composition | |
| CN103288820A (en) | Compound 13-methyl-palmatrubine and application thereof | |
| CN101070273A (en) | Anti-tumor compound trans-4-[2-(3,5,-dimethoxyphenyl) vinyl]-1,2-xyyl alcohol and preparing method therefor | |
| CN104825469A (en) | Application of cleistanone O-(benzimidazolyl) ethyl derivative in preparation of drugs for increasing leukocyte | |
| CN107311974A (en) | A kind of diclofenac coupled thing of bicyclic alcohols and its production and use | |
| CN115772144A (en) | Cannabinoid compounds, preparation method and application thereof | |
| CN105832742A (en) | Application of composition of Virosaine A pyrrolidine derivative and morpholinyl derivative to medicine for increasing leucocyte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110525 |